Millennium Management’s Revolution Medicines RVMD Stock Holding History

Millennium Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-35,000	Closed	-$2.79M	–	6296
2025 Q4	$2.79M	Sell	35,000 -46,000	-57%	-$3.02M	﹤0.01%	3635
2025 Q3	$3.78M	Buy	+81,000	New	+$3.17M	﹤0.01%	3425
2025 Q1	–	Sell	-20,000	Closed	-$875K	–	6331
2024 Q4	$875K	Sell	20,000 -45,000	-69%	-$2.27M	﹤0.01%	4309
2024 Q3	$2.95M	Buy	65,000 +27,400	+73%	+$1.19M	﹤0.01%	3337
2024 Q2	$1.46M	Sell	37,600 -92,400	-71%	-$3.45M	﹤0.01%	3797
2024 Q1	$4.19M	Buy	130,000 +108,800	+513%	+$3.22M	﹤0.01%	3052
2023 Q4	$608K	Sell	21,200 -97,800	-82%	-$2.35M	﹤0.01%	4524
2023 Q3	$3.29M	Buy	119,000 +35,000	+42%	+$1.04M	﹤0.01%	3112
2023 Q2	$2.25M	Buy	+84,000	New	+$2.06M	﹤0.01%	3373
2023 Q1	–	Sell	-95,300	Closed	-$2.27M	–	6786
2022 Q4	$2.27M	Buy	95,300 +35,000	+58%	+$744K	﹤0.01%	3467
2022 Q3	$1.19M	Buy	+60,300	New	+$1.33M	﹤0.01%	4188

Other funds holding RVMD

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management's RVMD Position: Q1 2026 in Review

Millennium Management reduced its Revolution Medicines (RVMD) stake by 53% in Q1 2026, selling an estimated $42.7M and leaving 377,332 shares worth $36.7M. The position accounts for 0.02% of the portfolio, ranked #1069.

Millennium Management first reported a position in RVMD in Q1 2020 and has held it in 20 quarters since. The position peaked at $63.7M in Q4 2025. 512 funds tracked by Wall St. Rank hold RVMD as of Q1 2026.

Millennium Management held 377,332 shares of Revolution Medicines worth $36.7M as of Q1 2026.
Millennium Management sold 422,786 Revolution Medicines shares in Q1 2026, an estimated $42.7M.
Revolution Medicines made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1069 holding.
Millennium Management first reported a position in Revolution Medicines in Q1 2020 and has held it in 20 quarters since.
Millennium Management's Revolution Medicines position peaked at $63.7M in Q4 2025.
512 funds tracked by Wall St. Rank held Revolution Medicines as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.